SENTI-101 / Senti Bio - LARVOL DELTA

SENTI-101, a preparation of mesenchymal stromal cells engineered to express IL-12 and IL-21, induces localized and durable anti-tumor immunity in preclinical models of peritoneal solid tumors. (PubMed, Mol Cancer Ther) - "Consistent with this mechanism of action, co-administration of mSENTI-101 with checkpoint inhibitors leads to synergistic improvement in anti-tumor response. Collectively, these data warrant potential clinical development of SENTI-101 for patients with peritoneal carcinomatosis and high-grade ovarian cancer."

Journal • Preclinical • Immune Modulation • Inflammation • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • IL12A • IL21

[VIRTUAL] SENTI-101, a novel genetically modified allogeneic cell product expressing IL12 and IL21, elicits a tumor-localized, robust, and multimodal immune response in preclinical models of solid tumors (AACR-II 2020) - "In accordance with increased T-cell infiltration and activation in the TME, SENTI-101 showed a synergistic anti-tumor effect when combined with checkpoint inhibitor anti-PD1. Overall, our preclinical studies show that SENTI-101 modulates the tumor immune landscape via multiple complementary modes of action, resulting in long-term anti-tumor immunity. Furthermore, this work demonstrates the therapeutic potential of tumor-localized cell therapies armed with gene circuits expressing combinatorial immune effectors to trigger a multi-factorial anti-tumor response."

IO Biomarker • Oncology • Peritoneal Cancer • Solid Tumor • CD38 • CXCL9 • GZMB • IFNG • IL12A • IL2RA